MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock and...
$216,169K
Proceeds from exercise of
stock options
$2,295K
Proceeds from issuance of
common stock under the...
$620K
Net cash provided by
financing activities
$218,867K
Canceled cashflow
$217K
Net (decrease)
increase in cash, cash...
-$25,275K
Canceled cashflow
$218,867K
Maturities of marketable
securities
$272,898K
Proceeds from sale of
property and equipment
$213K
Stock-based compensation
$34,019K
Accounts payable
$817K
Non-cash lease expense
$353K
Depreciation
$263K
Loss on disposal of
property and equipment
-$106K
Payment of deferred
offering costs
$217K
Net cash used in
investing activities
-$173,841K
Canceled cashflow
$273,111K
Net cash used in
operating activities
-$70,301K
Canceled cashflow
$35,558K
Purchases of marketable
securities
$446,794K
Purchases of property and
equipment
$158K
Net loss
-$103,694K
Prepaid expenses, other
current and long-term...
$1,105K
Accrued expenses and
other liabilities
-$496K
Operating lease
liabilities
-$337K
Amortization of premiums and
discounts on marketable...
$227K
Back
Back
Cash Flow
source: myfinsight.com
Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics, Inc. (ELVN)